Skip to main content
SpringerLink
Log in

Genetics of Ovarian Carcinomas

  • Chapter
  • First Online:
Ovarian Cancers

  • 1074 Accesses

Abstract

It is estimated that 15–20 % of ovarian carcinomas arise in women carrying a monoallelic germline cancer-predisposing gene mutation. The two main known hereditary forms of ovarian carcinoma are hereditary breast/ovarian cancer (HBOC) linked to BRCA1 or BRCA2 mutations, genes involved in DNA double-strand break repair by homologous recombination (HR), and Lynch syndrome linked to mutations in genes involved in DNA mismatch repair (MMR): MLH1, MSH2, MSH6 or PMS2. The contribution of BRCA1/BRCA2 mutations is at least tenfold higher than that of MMR genes. Identification of a cancer-predisposing mutation is useful for the prevention of breast, ovarian or colon cancers in affected women and their relatives and is now becoming a major part of the treatment of women with ovarian carcinoma, as poly-ADP-ribose-polymerase (PARP) inhibitors have been demonstrated to be useful in HBOC syndrome. New perspectives are opening up in Lynch syndrome with immunotherapy targeting Lynch syndrome-related cancers, characterised by their immunogenicity. Other genes involved in the HR pathway (PALB2, RAD51, ATM) are good candidates to be associated with an increased risk of ovarian and breast cancers that would be expected to be also sensitive to PARP inhibitors. As the identification of women harbouring germline or tumour inactivation of HR genes and probably, in the near future, MMR gene mutations is now becoming essential for their treatment, increasing test demands and the need for rapid and complete analyses are going to modify current genetic counselling and testing practices.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.

    Article  CAS  PubMed  Google Scholar 

  2. Wooster R, Bignell G, Lancaster J, Swift S, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789–92.

    Article  CAS  PubMed  Google Scholar 

  3. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996;12:333–7.

    Article  CAS  PubMed  Google Scholar 

  4. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, Lenoir GM. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet. 1991;338(8759):82–3.

    Article  CAS  PubMed  Google Scholar 

  5. INCa annual activity report 2013. http://www.e-cancer.fr/publications/59-recherche/811-synthese-de-lactivite-doncogenetique-2013-consultations-et-laboratoires

  6. Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Béroud C, Lidereau R, French BRCA GGC Consortium. Description and analysis of genetic variants in french hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases. Nucleic Acids Res. 2012;40(Database issue):D992–1002.

    Article  CAS  PubMed  Google Scholar 

  7. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, Radice P, Stoppa-Lyonnet D, Tavtigian S, Wappenschmidt B, Couch FJ, Goldgar DE. ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2012;33(1):2–7.

    Article  CAS  PubMed  Google Scholar 

  8. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88(2):265–75.

    Article  CAS  PubMed  Google Scholar 

  9. Foulkes WD, Shuen AY. In brief: BRCA1 and BRCA2. J Pathol. 2013;230(4):347–9.

    Article  CAS  PubMed  Google Scholar 

  10. Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7(4):a016600.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lee JM, Ledermann JA, Kohn EC. PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25(1):32–40.

    Article  PubMed  Google Scholar 

  12. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004;10(7):2473–81.

    Article  CAS  PubMed  Google Scholar 

  13. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121:353–7.

    Article  CAS  PubMed  Google Scholar 

  14. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284–93.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161–9.

    Article  PubMed  Google Scholar 

  16. Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J, Jimenez-Linan M, Gayther SA, Goode EL, Pharoah PD. The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 2014;23(17):4703–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Alsop K, Fereday S, Meldrum C, De Fazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654–63. Erratum in J Clin Oncol. 2012; 30(33):4180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Antoniou A, Pharoah PDP, Narod S, Risch A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in cases series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329–33.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313(13):1347–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2):164–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund M, Lichtner P, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410–4.

    Article  CAS  PubMed  Google Scholar 

  25. Loveday C, Turnbull C, Ramsay E, Hughes D, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Loveday C, Turnbull C, Ruark E, Xicola RM, Ramsay E, Hughes D, Warren-Perry M, Snape K, Breast Cancer Susceptibility Collaboration (UK). Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 2012;44(5):475–6.

    Article  CAS  PubMed  Google Scholar 

  27. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science. 1994;266(5182):120–2.

    Article  CAS  PubMed  Google Scholar 

  28. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.

    Article  Google Scholar 

  29. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–75.

    Article  CAS  PubMed  Google Scholar 

  30. Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012;72(21):5454–62.

    Article  CAS  PubMed  Google Scholar 

  31. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012;2(4):366–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, et al. TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer. J Clin Oncol 2015;33(17):1902–9.

    Google Scholar 

  34. Lynch HT, Shaw MW, Magnuson CW, et al. Hereditary factors in cancer: study of two large Midwestern kindreds. Arch Intern Med. 1966;117:206–12.

    Article  CAS  PubMed  Google Scholar 

  35. Piñol V, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Rodríguez-Moranta F, Payá A, Jover R, Bessa X, Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA. 2005;293(16):1986–94.

    Article  PubMed  Google Scholar 

  36. Martín-López JV, Fishel R. The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome. Fam Cancer. 2013;12(2):159–68.

    Article  PubMed  PubMed Central  Google Scholar 

  37. de la Chapelle A, Hampel A. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380–7.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US multi-society task force on colorectal cancer. Am J Gastroenterol. 2014;109(8):1159–79.

    Article  PubMed  Google Scholar 

  39. Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, et al. Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol. 2014;32(2):90–100.

    Article  CAS  PubMed  Google Scholar 

  40. Chui MH, Gilks CB, Cooper K, et al. Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Adv Anat Pathol. 2013;20:378–86.

    Article  CAS  PubMed  Google Scholar 

  41. Chui MH, Ryan P, Ferguson SE, Pollett A, Aronson M, Semotiuk K, et al. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. Am J Surg Pathol. 2014;38(9):1173–81.

    Article  PubMed  Google Scholar 

  42. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–43.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Niskakoski A, Kaur S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP, Bützow R, Peltomäki P. Distinct molecular profiles in Lynch syndrome-associated and sporadic ovarian carcinomas. Int J Cancer. 2013;133(11):2596–608.

    CAS  PubMed  Google Scholar 

  44. Salovaara R, Loukola A, Kristo P, Kääriäinen H, Ahtola H, Eskelinen M, Härkönen N, Julkunen R, Kangas E, Ojala S, Tulikoura J, Valkamo E, Järvinen H, Mecklin JP, Aaltonen LA, de la Chapelle A. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol. 2000;18(11):2193–200.

    CAS  PubMed  Google Scholar 

  45. Pal T, Akbari MR, Sun P, Lee JH, Fulp J, Thompson Z, Coppola D, et al. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br J Cancer. 2012;107(10):1783–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, Guimbaud R, Buecher B, French Cancer Genetics Network, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305(22):2304–10.

    Article  CAS  PubMed  Google Scholar 

  47. Radman M, Wagner R. Carcinogenesis. Missing mismatch repair. Nature. 1993;366(6457):722.

    Article  CAS  PubMed  Google Scholar 

  48. Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer Discov. 2015;5(1):16–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Schwart MD, Valdimarsdottir HB, Peshkin BN, Mandelblatt J, Nusbaum R, Huang AT, Chang Y, Graves K, et al. Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol. 2014;32(7):618–26.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Tumour Biology, Institut Curie, Paris, France

    Claire Sénéchal, Bruno Buecher, Antoine de Pauw, Claude Houdayer, Etienne Rouleau & Dominique Stoppa-Lyonnet

  2. Institut Curie, INSERM U830, Paris, France

    Claude Houdayer & Dominique Stoppa-Lyonnet

  3. Université Paris Descartes, Sorbonne Paris-Cité, Paris, France

    Claude Houdayer & Dominique Stoppa-Lyonnet

  4. Department of Tumour Biology, Institut Curie, Saint-Cloud, France

    Catherine Noguès

Authors
  1. Claire Sénéchal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruno Buecher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antoine de Pauw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claude Houdayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Etienne Rouleau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Catherine Noguès
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dominique Stoppa-Lyonnet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominique Stoppa-Lyonnet .

Editor information

Editors and Affiliations

  1. AP-HP, Hôtel-Dieu, Paris, France

    Eric Pujade-Lauraine

  2. Centre Léon Bérard, Université Claude Bernard, Lyon, France

    Isabelle Ray-Coquard

  3. Chirurgie cancérologique, HEGP, Paris, France

    Fabrice Lécuru

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sénéchal, C. et al. (2017). Genetics of Ovarian Carcinomas. In: Pujade-Lauraine, E., Ray-Coquard, I., Lécuru, F. (eds) Ovarian Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-32110-3_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32110-3_2

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32108-0

  • Online ISBN: 978-3-319-32110-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation